Tetraphase Pharmaceuticals (NASDAQ:TTPH) will be releasing its earnings data after the market closes on Tuesday, November 12th. Analysts expect Tetraphase Pharmaceuticals to post earnings of ($7.20) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($8.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($7.60) by ($0.80). Tetraphase Pharmaceuticals had a negative net margin of 1,072.60% and a negative return on equity of 118.65%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $2.13 million. On average, analysts expect Tetraphase Pharmaceuticals to post $-25 EPS for the current fiscal year and $-8 EPS for the next fiscal year.
NASDAQ TTPH opened at $3.19 on Monday. The business has a fifty day moving average price of $3.71 and a 200 day moving average price of $1.35. Tetraphase Pharmaceuticals has a one year low of $3.05 and a one year high of $45.20. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.95 and a current ratio of 4.10. The company has a market cap of $8.77 million, a P/E ratio of -0.12 and a beta of 2.36.
Several research firms recently commented on TTPH. G.Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, October 31st. HC Wainwright restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Tuesday, November 5th. ValuEngine upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Gabelli upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, October 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, August 11th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $58.00.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Read More: 52- Week Highs
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.